NASDAQ:CODX - Co-Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.3180 +0.03 (+1.31 %)
(As of 11/13/2018 02:03 PM ET)
Previous Close$2.29
Today's Range$2.29 - $2.3240
52-Week Range$1.45 - $6.66
Volume2,648 shs
Average Volume322,394 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CODX
Previous Symbol
CUSIPN/A
Phone+1-801-2789769

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees17
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Has Co-Diagnostics been receiving favorable news coverage?

News headlines about CODX stock have trended positive this week, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Co-Diagnostics earned a news impact score of 2.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days.

Who are some of Co-Diagnostics' key competitors?

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the folowing people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 65)
  • Dr. Brent C. Satterfield, Co-Founder, Chief Science Officer & Director (Age 41)
  • Mr. Reed L. Benson, CFO, Gen. Counsel & Sec. (Age 70)

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $2.3180.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is http://codiagnostics.com/.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 4049 S Highland Dr, SALT LAKE CITY, UT 84124-1664, United States. The company can be reached via phone at +1-801-2789769.


MarketBeat Community Rating for Co-Diagnostics (NASDAQ CODX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  220
MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote "Outperform" if you believe CODX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel